[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
OBJECTIVE
To evaluate the toxicity and efficacy of capecitabine-based chemotherapy in the treatment of advanced gastric cancer.


METHODS
104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept. 2001 to May 2007. Group 1 was treated by capecitabine 1000 mg/m(2) orally twice daily on D1-14, repeated every 3 weeks;group 2 by capecitabine as that of group 1, and combined with paclitaxel 175 mg/m(2) intravenous infusion on D1 (or 80 - 90 mg/m(2) on D1, D8), or docetaxel 65 - 75 mg/m(2) on D1, repeated every 3 weeks; group 3 by capecitabine as that of group 1, combined with cisplatin 15 - 20 mg/m(2) intravenous infusion for 2 h on D1-5, or oxaliplatin 130 mg/m(2) for 2 h on D1, repeated every 3 weeks. The median cycles of treatment were 3 cycles.


RESULTS
The overall response rate was 20.6%. The median overall survival and the median time to progression were 8.5 months and 5.2 months, respectively. For the first-line chemotherapy, ORR was 40.0%, disease control rate was 76.7%; the median overall survival in all patients and in the patients with first-line chemotherapy of capecitabine plus paclitaxel were 10.9 months and 12.8 months, respectively. The adverse events in capecitabine alone group were the least among all the groups.


CONCLUSIONS
The capecitabine-based chemotherapy was effective and tolerable. The patients with KPS < 80 may choose capecitabine alone for the chemotherapy. The regimen of capecitabine combined with paclitaxel was more effective than other regimens. However, further investigation to improve it is still required.
Zhang
Jie
J
Department of Gastrointestinal Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
Xiao
Ya
Y
Lu
Ming
M
Li
Jie
J
Zhang
Xiao-dong
XD
Li
Yan
Y
Shen
Lin
L
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced; D055815:Young Adult
D009944:Organoplatinum Compounds; D043823:Taxoids; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil